^
    Apply
    Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1) (NCT04486833)
    Phase 1/2
    Genprex, Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/03/2021
    Primary completion :
    03/01/2028
    Completion :
    03/01/2029
    EGFR
    |
    EGFR mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • Reqorsa (quaratusugene ozeplasmid)
    Lurbinectedin in FET-Fused Tumors (LiFFT) (NCT05918640)
    Phase 1/2
    Children's Hospital of Philadelphia
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/27/2023
    Primary completion :
    07/30/2026
    Completion :
    07/30/2028
    EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4
    |
    Zepzelca (lurbinectedin)
    Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer (LURBIMUNE) (NCT05572476)
    Phase 2
    Institut Bergonié
    Withdrawn
    Last update posted :
    06/05/2024
    Initiation :
    10/01/2023
    Primary completion :
    05/31/2024
    Completion :
    05/31/2024
    PD-L1
    |
    carboplatin • Imfinzi (durvalumab) • etoposide IV • Zepzelca (lurbinectedin)
    Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 (NCT04874194)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    12/17/2021
    Primary completion :
    08/01/2024
    Completion :
    08/01/2024
    RUNX1
    |
    RUNX1 mutation
    |
    Venclexta (venetoclax) • Synribo (omacetaxine mepesuccinate)
    Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors (PM1183-A-014-15) (NCT02611024)
    Phase 1/2
    PharmaMar
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    05/06/2016
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    PD-L1
    |
    irinotecan • Zepzelca (lurbinectedin)
    Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma (NCT03696784)
    Phase 1
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    04/26/2024
    Initiation :
    03/12/2019
    Primary completion :
    03/22/2027
    Completion :
    03/22/2043
    ALK • BCL2 • BCL6 • IRF4
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • rimiducid (AP1903)
    Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL (NCT03016377)
    Phase 1/2
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    03/22/2012
    Primary completion :
    04/22/2026
    Completion :
    04/22/2041
    ABL1 • BCR • CD19
    |
    CD19 positive • CD19 expression
    |
    cyclophosphamide • fludarabine IV • iC9-CAR19 cells • rimiducid (AP1903)
    INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study (NCI-2020-02940) (NCT04445844)
    Phase 2
    Mridula George, MD
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    07/13/2020
    Primary completion :
    06/30/2024
    Completion :
    09/30/2024
    HER-2 • ER • PGR
    |
    PD-L1 expression • HER-2 expression • ER expression
    |
    Irene (pyrotinib) • Zynyz (retifanlimab-dlwr) • Reolysin (pelareorep)
    Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer (NCT05800587)
    Phase 2
    Fox Chase Cancer Center
    Recruiting
    Last update posted :
    03/26/2024
    Initiation :
    02/22/2023
    Primary completion :
    08/01/2028
    Completion :
    08/01/2029
    CD4
    |
    carboplatin • gemcitabine • docetaxel • albumin-bound paclitaxel • pemetrexed • etoposide IV • irinotecan • topotecan • Zepzelca (lurbinectedin)
    Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. (NCT06328179)
    Phase N/A
    Huai'an First People's Hospital
    Recruiting
    Last update posted :
    03/25/2024
    Initiation :
    05/24/2022
    Primary completion :
    12/30/2027
    Completion :
    12/30/2027
    BCL2
    |
    Venclexta (venetoclax) • cytarabine • etoposide IV • Synribo (omacetaxine mepesuccinate)
    NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors (NCT05661201)
    Phase 1
    Georgetown University
    Recruiting
    Last update posted :
    03/11/2024
    Initiation :
    04/12/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    KRAS • ST2
    |
    KRAS mutation
    |
    doxorubicin hydrochloride • Nerofe (84AA-API 14AA)
    Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201) (NCT05126433)
    Phase 2
    Jazz Pharmaceuticals
    Completed
    Last update posted :
    02/26/2024
    Initiation :
    03/03/2022
    Primary completion :
    12/20/2023
    Completion :
    12/20/2023
    HER-2 • HRD
    |
    HER-2 negative
    |
    Zepzelca (lurbinectedin)
    Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma (NCT02704858)
    Phase 1/2
    Neonc Technologies, Inc.
    Recruiting
    Last update posted :
    02/15/2024
    Initiation :
    04/08/2016
    Primary completion :
    06/01/2024
    Completion :
    12/01/2024
    IDH1
    |
    IDH1 mutation
    |
    perillyl alcohol (NEO100)
    Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations (NCT05229588)
    Phase 2
    HonorHealth Research Institute
    Recruiting
    Last update posted :
    02/02/2024
    Initiation :
    06/14/2022
    Primary completion :
    08/31/2025
    Completion :
    08/31/2026
    BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY
    |
    BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation
    |
    Zepzelca (lurbinectedin)
    A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (NCT02653976)
    Phase 2
    Solasia Pharma K.K.
    Completed
    Last update posted :
    01/26/2024
    Initiation :
    03/25/2016
    Primary completion :
    10/11/2020
    Completion :
    06/17/2021
    ALK
    |
    ALK positive
    |
    Zinapar (darinaparsin)
    Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer (NCT04120246)
    Phase 1
    Veana Therapeutics
    Recruiting
    Last update posted :
    12/12/2023
    Initiation :
    04/08/2020
    Primary completion :
    02/01/2024
    Completion :
    02/01/2025
    HER-2 • PGR
    |
    HER-2 positive • HER-2 overexpression • PGR positive
    |
    Herceptin (trastuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • GB221 (coprelotamab) • Vimo (alpha-tocopheroloxyacetic acid)
    A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study (NCT04215146)
    Phase 2
    Oncolytics Biotech
    Active, not recruiting
    Last update posted :
    11/30/2023
    Initiation :
    06/10/2020
    Primary completion :
    08/01/2022
    Completion :
    07/01/2024
    ER • PGR
    |
    HER-2 overexpression
    |
    paclitaxel • Bavencio (avelumab) • Reolysin (pelareorep)
    Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer (NCT05519059)
    Phase 1
    Adlai Nortye Biopharma Co., Ltd.
    Completed
    Last update posted :
    11/22/2023
    Initiation :
    10/11/2021
    Primary completion :
    09/29/2022
    Completion :
    05/30/2023
    HER-2 • ER • PGR
    |
    HER-2 overexpression
    |
    paclitaxel • Reolysin (pelareorep)
    Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial (NCT05514990)
    Phase 1/2
    University of Southern California
    Recruiting
    Last update posted :
    11/17/2023
    Initiation :
    10/07/2022
    Primary completion :
    10/07/2025
    Completion :
    10/07/2026
    CD8 • PD-1 • IFNG • CD4 • GZMB
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • bortezomib • Reolysin (pelareorep) • Hemady (dexamethasone tablets) • dexamethasone injection
    Study of Trilaciclib and Lurbinectidin (NCT05578326)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    11/16/2023
    Initiation :
    10/12/2022
    Primary completion :
    07/25/2024
    Completion :
    07/25/2026
    PD-L1
    |
    Zepzelca (lurbinectedin) • Cosela (trilaciclib)
    Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064) (NCT02688140)
    Phase 3
    Technische Universität Dresden
    Active, not recruiting
    Last update posted :
    11/02/2023
    Initiation :
    06/01/2016
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    PML
    |
    PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion
    |
    cytarabine • idarubicin hydrochloride • mitoxantrone • arsenic trioxide • mercaptopurine
    Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer (NCT04607954)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    07/24/2023
    Initiation :
    12/04/2020
    Primary completion :
    11/01/2024
    Completion :
    11/01/2025
    PD-L1
    |
    Imfinzi (durvalumab) • topotecan • Zepzelca (lurbinectedin)
    T-Cell Therapy for Advanced Breast Cancer (NCT02792114)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    06/30/2023
    Initiation :
    06/01/2016
    Primary completion :
    06/01/2024
    Completion :
    06/01/2024
    HER-2 • PD-L1 • MSLN
    |
    HER-2 negative • MSLN expression
    |
    cyclophosphamide • rimiducid (AP1903)
    An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors (NCT01397929)
    Phase 1/2
    Basilea Pharmaceutica
    Completed
    Last update posted :
    05/10/2023
    Initiation :
    06/01/2011
    Primary completion :
    01/01/2016
    Completion :
    04/01/2016
    MUC16
    |
    lisavanbulin (BAL101553)
    Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NCT04840004)
    Phase 2
    PlusVitech S.L.
    Recruiting
    Last update posted :
    04/05/2023
    Initiation :
    03/10/2021
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    EGFR • ROS1
    |
    PVT-1
    Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors (NCT02454972)
    Phase 2
    PharmaMar
    Completed
    Last update posted :
    03/02/2023
    Initiation :
    08/25/2015
    Primary completion :
    09/18/2020
    Completion :
    09/18/2020
    BRCA1 • BRCA2 • BRCA
    |
    Zepzelca (lurbinectedin)
    Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancer (NCT05721872)
    Phase 1/2
    Nazarbayev University
    Recruiting
    Last update posted :
    02/10/2023
    Initiation :
    02/15/2023
    Primary completion :
    08/01/2023
    Completion :
    11/01/2023
    KRAS
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • arsenic trioxide
    Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer (GEN-602-CT-101) (NCT03775525)
    Phase 1
    Genzada Pharmaceuticals USA, Inc.
    Active, not recruiting
    Last update posted :
    12/23/2022
    Initiation :
    03/01/2019
    Primary completion :
    05/01/2023
    Completion :
    12/01/2023
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    capecitabine • GZ17-6.02
    Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS (PANDA-T0) (NCT03855371)
    Phase 1
    Ruijin Hospital
    Recruiting
    Last update posted :
    11/04/2022
    Initiation :
    01/10/2018
    Primary completion :
    07/01/2023
    Completion :
    07/01/2024
    TP53
    |
    TP53 mutation
    |
    decitabine • arsenic trioxide
    Phase III Trial in Acute Promyelocytic Leukemia Patients (APL0406) (NCT00482833)
    Phase 3
    Gruppo Italiano Malattie EMatologiche dell'Adulto
    Completed
    Last update posted :
    10/11/2022
    Initiation :
    08/01/2007
    Primary completion :
    09/01/2012
    Completion :
    10/17/2019
    PML
    |
    PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion
    |
    idarubicin hydrochloride • arsenic trioxide • mercaptopurine
    Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML (NCT04365179)
    Phase 1b
    Immune System Key Ltd
    Recruiting
    Last update posted :
    07/22/2022
    Initiation :
    06/18/2020
    Primary completion :
    12/30/2022
    Completion :
    12/30/2022
    ST2
    |
    Nerofe (84AA-API 14AA)
    Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant (NCT03459170)
    Phase 1
    Bellicum Pharmaceuticals
    Active, not recruiting
    Last update posted :
    07/12/2022
    Initiation :
    02/01/2018
    Primary completion :
    09/01/2022
    Completion :
    09/01/2035
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)
    Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma (NCT05042934)
    Phase 1b/2
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    02/10/2022
    Initiation :
    09/15/2021
    Primary completion :
    08/30/2022
    Completion :
    08/30/2022
    EWSR1 • FLI1 • WRN • RECQL
    |
    irinotecan • Zepzelca (lurbinectedin)
    Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML (NCT00462943)
    Phase 2
    Teva Branded Pharmaceutical Products R&D, Inc.
    Completed
    Last update posted :
    12/28/2021
    Initiation :
    03/07/2007
    Primary completion :
    08/04/2009
    Completion :
    06/27/2013
    ABL1 • BCR
    |
    Synribo (omacetaxine mepesuccinate)
    Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy (NCT01404949)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    11/30/2021
    Initiation :
    07/01/2011
    Primary completion :
    02/01/2021
    Completion :
    02/01/2021
    TERT • PML
    |
    arsenic trioxide
    Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation (NCT00375219)
    Phase 2
    Teva Branded Pharmaceutical Products R&D, Inc.
    Completed
    Last update posted :
    11/15/2021
    Initiation :
    09/20/2006
    Primary completion :
    03/23/2010
    Completion :
    06/28/2013
    ABL1 • BCR
    |
    Synribo (omacetaxine mepesuccinate)